New options for treatment of chronic pain syndrome

Cover Page

Cite item

Full Text

Abstract

According to the World Health Organization, 12.6 million new cases of cancer were identified in 2008. In 2022, this number reached 18.1 million cases, and it is projected to increase to 26 million in 2040. Chronic pain is defined by the International Association for the Study of Pain as pain that persists or recurs for 3 months. A similar definition is given in the International Classification of Diseases, 11th revision, which for the first time includes chronic pain as an independent category with a unique code MG30. The incidence of pain syndrome in advanced terminal or metastatic stages of cancer is 64 %, during antitumor therapy – 59 %, after successful treatment – 33 %. However, side effects from opioids significantly worsen the quality of life of patients.

A new type of peptide drugs can reduce the toxic effects of drug pain therapy.

About the authors

L. M. Kogoniya

Department of Oncology and Thoracic Surgery of the Faculty of Advanced Medicine, M.F. Vladimirsky Moscow Regional Clinical Research Institute

Author for correspondence.
Email: lali51@yandex.ru
ORCID iD: 0000-0003-3326-4961

Lali Mikhaylovna Kogoniya

61/2 Shchepkina St., Moscow 129110

Russian Federation

References

  1. Aldrich J.V., McLaughlin J.P. Opioid peptides: potential for drug development. Drug Discov Today Technol 2012;9(1):e23–31. doi: 10.1016/j.ddtec.2011.07.007
  2. Broccardo M., Erspamer V., Falconieri Erspamer G. et al. Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin. Br J Pharmacol 1981;73(3):625–31. doi: 10.1111/j.1476-5381.1981.tb16797.x
  3. Mizoguchi H., Bagetta G., Sakurada T., Sakurada S. Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine. Peptides 2011;32(2):421–7. doi: 10.1016/j.peptides.2010.11.013
  4. Chaki K., Sakurada S., Sakurada T. et al. N-terminal tetrapeptide of dermorphin and D-Arg-substituted tetrapeptides: inactivation process of the antinociceptive activity by peptidase. Life Sci 1990;46(23):1671–8. doi: 10.1016/0024-3205(90)90382-2
  5. Sasaki Y., Matsui M., Fujita H. et al. The analgesic activity of D-Arg2-dermorphin and its N-terminal tetrapeptide analogs after subcutaneous administration in mice. Neuropeptides 1985;5(4–6): 391–4. doi: 10.1016/0143-4179(85)90036-8
  6. Kosorukov V.S., Rzhaninov E.S., Korobov N.V. Means for effective cupping of acute and/or chronic pain syndrome and method of its application. Patent RU 2622980 C1, 12.08.2016. Application No. 2016133329. (In Russ.).
  7. Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors 2022;12(2):89–107. (In Russ.). doi: 10.17650/2222-1468-2022-12-2-89-107
  8. Tafalgin. medicinal product registration certificate for medical use. LP-No.(001039)-(РГ-RU). (In Russ.).
  9. State Register of medicinal Remedies. Tafalgin. No. FS-001964. Available at: https://zdravmedinform.ru/grls/reg-fs-001964.html (In Russ.).
  10. Voronina T.A., Guzevatykh L.S. methodological guidelines on study of analgesic activity of medicinal products. In: Guidelines on preclinical study of medicinal products. Part one. moscow: Grif i K., 2012. Pp. 197–218. (In Russ.).
  11. Bannon A.W., malmberg A.B. models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci 2007;Chapter 8:Unit 8.9. doi: 10.1002/0471142301.ns0809s41
  12. Karelov A.E., Kosorukov V.S., Kraevskaya Yu.N. et al. Effectiveness of the new peptide analgesic Tafalgin in the treatment of postoperative pain. Anesteziologiya i reanimatologiya = Russian Journal of Anesthesiology and Reanimatology 2023;(6):75–83. (In Russ.). doi: 10.17116/anaesthesiology202306175
  13. Abuzarova G.R., Kosorukov V.S., Gamzeleva O.Yu. et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2022;11(5):38–48. (In Russ.). doi: 10.17116/onkolog20221105138

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Kogoniya L.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-86325 от  11.12.2023.